Trial Profile

A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CCT303-406 (Primary) ; Cyclophosphamide; Fludarabine
Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Shanghai PerHum Therapeutics

23 Jan 2025 Status changed from active, no longer recruiting to completed, according to EXUMA Biotech media release.
23 Jan 2025 According to an EXUMA Biotech media release, company presented data from this study at the ASCO Gastrointestinal Cancers Symposium.
28 Oct 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com